a website banner telling users to subscribe to it's newsletter

Sheikh Shakhbout Medical City Introduces Novel Medication for TED

Sheikh Shakhbout Medical City Introduces Novel Medication for TED

September 18, 2023

Sheikh Shakhbout Medical City (SSMC), a joint-venture partnership between Abu Dhabi Health Services Company (SEHA) and Mayo Clinic, has introduced an innovative medication, approved by the FDA, for patients with thyroid eye disease (TED).

SSMC, renowned for housing one of the largest ophthalmology units in the UAE, has successfully secured and now administers this medication, which mitigates the effects of this debilitating autoimmune disease.

Teprotumumab-trbw, a monoclonal antibody therapy, works by obstructing specific proteins in the body, leading to a reduction in inflammation. Consequently, patients experience improvements in vision, relief from pain, diminished redness, reduced swelling, alleviation of double vision, and a reduction in protruding eyes.

The patient who received this groundbreaking therapy sought treatment at SSMC due to blurred vision and eye discomfort in both eyes. He endured constant redness and excessive tearing, significantly impacting his vision and overall quality of life. Under the care of Dr. Habibullah Eatamadi, consultant oculoplastic and ophthalmic surgeon, and Dr. Ohood Almazrouie, oculoplastic and ophthalmic surgeon at SSMC, comprehensive tests and examinations confirmed a diagnosis of severe thyroid eye disease, posing a significant threat to his eyesight.

After thorough discussions regarding treatment options, the patient opted for the only FDA-approved medication for thyroid eye disease. Subsequently, he witnessed remarkable progress in his journey to recovery, experiencing a substantial enhancement in his overall well-being and improved ability to manage his daily activities.

Dr. Eatamadi said: “Introducing this much-needed medication to the region presents patients suffering from TED with an effective solution to their condition. By making the treatment available at SSMC, we are contributing to reducing the risk of patients facing irreversible eye damage. Moreover, what makes this medication truly unique is its ability to treat the cause of the disease and not just the symptoms of TED.”

Marleine Bejjani Moukarzel, director of Pharmacy, added: “SSMC boasts a team of exceptionally skilled clinical pharmacists, who play a pivotal role in the evaluation and implementation of cutting-edge advancements and therapeutic approaches. We are committed to providing pioneering medicines to all patients in the most effective and compassionate way”.

Dr. Matthew Gettman, chief medical officer, at SSMC, remarked the importance of making novel treatments available to patients with autoimmune disorders and said: “Introducing novel treatments that address patients’ needs will always be an absolute priority for SSMC. We remain committed to the provision of exceptional health care and work tirelessly to provide integrated and progressive solutions for patients in the region and beyond. “